Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDA53: Ibrutinib + Daratumumab in Relapsed/Refractory CLL with TP53 Dysfunction
2018-001777-25Phase 2Completed
- Sponsor
- Filo
- Start
- Aug 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and daratumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Filo. Primary endpoint: Complete response rate at 12 months. Started Aug 2018; status: completed.
02
Drugs
ibrutinibdaratumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2018-001777-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001777-25.